Liquidia Corporation to Host 2020 Financial Results Conference Call on March 23, 2021
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Liquidia Corporation (NASDAQ: LQDA) will announce its 2020 financial results on March 23, 2021, followed by a webcast and conference call at 8:30 a.m. ET. The call can be accessed via phone or through their website. Liquidia specializes in developing treatments for pulmonary hypertension and other applications using its PRINT technology. Its key product candidates include LIQ861 for pulmonary arterial hypertension and LIQ865 for post-operative pain management.
Positive
- Upcoming announcement of 2020 financial results may indicate strategic growth.
- Focus on innovative treatments for pulmonary hypertension could enhance market position.
Negative
- None.
Details
News Market Reaction – LQDA
The recorded move for LQDA in the trading session of this news was +9.13%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
RESEARCH TRIANGLE PARK, N.C., March 09, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced that 2020 financial results will be reported on Tuesday, March 23, 2021. The company will host a webcast and conference call at 8:30 a.m. ET to discuss financial results and provide a corporate update.
The live call may be accessed by dialing 1-877-707-8711 (domestic) or 1-857-270-6219 (international) and entering the conference code: 5167825. A live and archived webcast of the call will be available on the Events & Presentations page of Liquidia’s website.
About Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company focused on the development and commercialization of products in pulmonary hypertension and other applications of its PRINT technology. The Company operates through two subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Liquidia Technologies is developing two product candidates: LIQ861, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH), and LIQ865, an injectable, sustained-release formulation of bupivacaine for the management of local post-operative pain for three to five days after a procedure. Liquidia PAH, LLC provides commercialization for rare disease pharmaceutical products, such as Treprostinil Injection, Sandoz Inc.’s first-to-file, generic treprostinil for PAH.
Liquidia Corporation is headquartered in Research Triangle Park, NC. For more information, please visit www.liquidia.com.
Contact Information
Media & Investors:
Jason Adair
Vice President, Corporate Development and Strategy
919.328.4400
jason.adair@liquidia.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.